Oruka Therapeutics, Inc. (ORKA) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2025.
Company Overview: Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. The company was formed via a reverse recapitalization in August 2024, changing its name from ARCA biopharma, Inc. to Oruka Therapeutics, Inc.
Key Programs:
- ORKA-001: Lead program targeting IL-23p19 for PsO. Designed with YTE half-life extension technology to enable dosing as infrequently as once or twice per year. Phase 1 data (announced Sept 2025) showed a human half-life of ~100 days. Phase 2a (EVERLAST-A) commenced Q3 2025; Phase 2b (EVERLAST-B) commenced December 2025.
- ORKA-002: Co-lead program targeting IL-17A/F for PsO, hidradenitis suppurativa (HS), and psoriatic arthritis (PsA). Phase 1 data (announced Jan 2026) showed a half-life of ~75-80 days. Phase 2 (ORCA-SURGE) initiated February 2026.
- ORKA-003: Third program targeting an undisclosed pathway.
Financial Metrics
| Metric (in millions) | Year Ended Dec 31, 2025 | Period Feb 6, 2024 - Dec 31, 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(105.4) | $(83.7) |
| Operating Expenses | $(122.1) | $(88.1) |
| Research & Development (R&D) | $(100.6) | $(75.1) |
| General & Administrative (G&A) | $(21.4) | $(13.1) |
| Net Cash Used in Operating Activities | $(88.2) | $(57.8) |
| Cash, Cash Equivalents, and Marketable Securities | $479.6 | $384.3 |
| Accumulated Deficit | $(189.2) | $(83.7) |
Debt and Liquidity: The company has no outstanding debt as of December 31, 2025 (a convertible note was converted to equity in 2024). As of December 31, 2025, the company held $479.6 million in cash, cash equivalents, and marketable securities. Management expects these resources to fund operations for at least twelve months from the filing date.
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by 39% to $122.1 million in 2025 compared to $88.1 million in the prior period. R&D expenses rose 34% to $100.6 million, driven by increased external costs (CROs/CMOs) and personnel-related expenses. G&A expenses increased 64% to $21.4 million due to hiring and professional fees.
- Capital Raises: The company completed a 2025 PIPE Financing in September 2025, raising net proceeds of approximately $169.6 million. In October 2025, an at-the-market (ATM) offering program was established with a capacity of $200.0 million; subsequent to year-end, $38.9 million was raised under this program.
- Development Progress: Significant advancement in clinical trials for both lead programs, moving from Phase 1 into Phase 2a and Phase 2b for ORKA-001, and initiating Phase 2 for ORKA-002.
Guidance, Outlook, and Risks
Outlook: The company anticipates sharing Week 16 data for ORKA-001 in Q2 2026 and longer-term data in H2 2026. Data for ORKA-002 Phase 2 is anticipated in 2027. The company expects to continue incurring significant losses as it advances clinical development.
Key Risks:
- Clinical Development: Failure of clinical trials to demonstrate safety or efficacy, or delays in enrollment and data readouts.
- Capital Requirements: Need to raise substantial additional capital to fund operations; inability to do so could force curtailment of programs.
- Regulatory Approval: Lengthy and uncertain FDA approval process; potential for rejection or requirement of additional studies.
- Third-Party Reliance: Dependence on Paragon Therapeutics for IP and WuXi Biologics for manufacturing. Risks include the BIOSECURE Act potentially restricting use of Chinese CMOs.
- Competition: Intense competition in the PsO market from established therapies (e.g., Skyrizi, Bimzelx) and new entrants.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $479.6 million cash balance against projected burn rates for 2026-2027 clinical trials.
- Paragon Agreements: Review the milestone payment obligations (up to $12M clinical, $10M regulatory per program) and royalty terms with Paragon Therapeutics.
- Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act on the company's reliance on WuXi Biologics and the feasibility of transitioning to alternative CMOs if required.
- Clinical Trial Design: Scrutinize the Phase 2 trial designs (EVERLAST-A/B and ORCA-SURGE) regarding the primary endpoint (PASI 100) and the statistical power to demonstrate superiority or non-inferiority to standard of care.
- Stock-Based Compensation: Note the significant non-cash expense ($24.2 million in 2025) and its impact on future dilution.